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Abstract
Background: The purpose of our study was to examine the association of prior outpatient use of
statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of
age hospitalized with acute COPD exacerbations.
Methods:  We conducted a retrospective national cohort study using Veterans Affairs
administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our
primary analysis was a multilevel model with the dependent variable of 90-day mortality and
hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and
other medications prescribed.
Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4%
of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using
statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting
for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40–0.64)
and ACE inhibitor/ARB use (0.55, 0.46–0.66) were significantly associated with decreased 90-day
mortality.
Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased
mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are
needed to examine whether the use of these medications are protective for those patients with
COPD exacerbations.
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Introduction
In the United States chronic obstructive pulmonary dis-
ease (COPD) is the 4th leading cause of death overall [1],
and is frequently complicated by recurrent acute exacerba-
tions, which are nationally responsible for 110,000
deaths and >500,000 hospitalizations per year [2].
Although extensive research on therapies has been con-
ducted to improve survival for patients with COPD so far
only oxygen therapy, lung volume reduction surgery, and
smoking cessation have been definitively demonstrated to
improve survival for patients with COPD [3].
In COPD, airway pro-inflammatory cytokine levels have
been demonstrated to be associated with increased airway
obstruction and exaggerated airway inflammatory
response [4,5]. In addition, elevated levels of pro-inflam-
matory cytokines, including IL-8 and TNF-alpha, have
been associated with increased incidence of respiratory
infections [6] and worse clinical outcomes including
increased mortality and poor health status [7-10]. Several
studies have demonstrated that HMG-CoA reductase
inhibitors ("statins") and angiotensin converting enzyme
(ACE) inhibitors have significant immunomodulatory
effects and reduce systemic cytokine levels [11-15]. There
have been several recent pharmacoepidemiologic studies
that have demonstrated that statin [16-19] and/or ACE
inhibitor use [17] were associated with improved out-
comes for patients hospitalized with acute COPD exacer-
bations or for those with pre-existing COPD. However
these studies all had important limitations including
small sample sizes from single sites, incomplete risk
adjustment, or not using techniques to minimize immor-
tal time bias. Therefore further research is needed to clarify
the roles and importance of these medications in the treat-
ment of patients with acute exacerbation of COPD.
The study aims were to assess the association of the use of
statins and ACE inhibitors on mortality in a population of
largely male subjects ≥ 65 years of age hospitalized with
acute COPD exacerbations after adjusting for other poten-
tial confounders using the extensive administrative data-
bases of the Department of Veterans Affairs (VA).
Methods
This study was conducted with VA inpatient and outpa-
tient administrative data that was collected as part of a
larger study of inappropriate prescribing practices in the
elderly [20]. The Institutional Review Board of the Univer-
sity of Texas Health Science Center at San Antonio classi-
fied this as an exempt study.
Inclusion and Exclusion Criteria
Subjects who were: a) aged 65 and older on October 1
1999, b) had at least one outpatient clinic visit during fis-
cal year (FY) 1999 (October 1 1998 – September 30
1999), c) were hospitalized during FY 2000 with a pri-
mary discharge diagnosis of acute exacerbation of COPD
(International Classification of Disease-9 codes 490–
492.8, 494, 496), d) and received at least one of the fol-
lowing respiratory medication(s) within 90-days of pres-
entation (e.g. any form of β-agonist, inhaled
corticosteroid, tiotroprium, or ipratropium.) We excluded
subjects with a history of asthma. If a subject was admitted
more than once during the study period, only the first
hospitalization was included. Unfortunately pulmonary
function test data was not available as part of these data-
bases to confirm the diagnosis of COPD. However a
recent publication by Joo et al., using a similar methodol-
ogy to define COPD demonstrated that >90% of subjects
were Global Initiative on Chronic Obstructive Lung Dis-
ease class 3–4 [21].
Data
This study used data from the National Patient Care Data-
base at the Austin Automation Center, pharmacy data
from the VA Pharmacy Benefit Management group, and
vital status data from the Beneficiary Identification
Records Locator Subsystem death file and inpatient por-
tion of the National Patient Care Database. Encrypted
patient identifiers were used to link the information from
each database for each subject.
Demographic information (age, sex, race, marital status,
socioeconomic status) was obtained from inpatient and
outpatient data. Missing race data were supplemented
using self-reported race from the 1999 Large Health Sur-
vey of Veterans, a nationally representative survey of VA
enrollees (July 1, 1999 – January 1, 2000) [22]. Race cate-
gories included white, black, Hispanic, and other/
unknown. In addition, we utilized information on the VA
means test as a surrogate for income.
Comorbid conditions were obtained from inpatient and
outpatient administrative data. Charlson's comorbidity
score was used to assign a comorbidity score for preexist-
ing comorbid conditions [23,24]. Charlson's comorbidity
score is based on 19 comorbid conditions each of which
has an associated prognostic weight ranging from 1 to 6.
Age was not included in the Charlson's score and was eval-
uated separately.
Pharmacy data were obtained from the Pharmacy Benefits
Management group databases. Subjects were considered a
"current user" of a given medication if their last filled pre-
scription included enough pills to last until the date of
hospitalization assuming an 80% compliance rate, which
is based on prior research of medication compliance
[25,26]. Medications classified as statins were atorvasta-
tin, cerivastatin, fluvastatin, lovastatin, pravastatin, and
simvastatin. Medications classified as ACE inhibitors wereRespiratory Research 2009, 10:45 http://respiratory-research.com/content/10/1/45
Page 3 of 9
(page number not for citation purposes)
benazepril, captopril, enalapril, fosinopril, lisinopril,
moexipril, quinapril, and ramipril. In addition, we
included angiotensin II receptor blockers (ARBs) in the
ACE inhibitor category for the analysis due to the small
number of subjects using this class of medications. ARBs
included candesartan, irbesartan, losartan, telmisartan,
and valsartan.
To further control for potential confounding by medica-
tions, a count of unique drugs in each of the following
classes per patient was calculated for drugs refilled/filled
within 90-days of presentation: cardiac medications
(excluding statins, ACE inhibitors, ARBS, and non-statin
lipid lowering agents), diabetic medications, and respira-
tory medications. Respiratory medications included
short-acting bronchodilators (albuterol, terbutaline, ipra-
tropium), long-acting inhaled bronchodilators (salme-
terol, formoterol and tiotropium), and theophylline. Two
dichotomized variables were created for corticosteroid
use: one for inhaled steroids and another for oral steroids.
Previous research has demonstrated that using the count
of these medication classes is preferable to adjusting for
the individual medications [27].
In addition, we created a category of non-statin lipid low-
ering agents (e.g. niacin, bile acid sequestrants, and fibric
acid derivatives) filled within 90-days of hospital presen-
tation so as to examine confounding in our models.
Outcome
Our primary outcome, 90-day mortality, was assessed
using the Beneficiary Identification Records Locator Sub-
system and the National Patient Care Database. Previous
studies have demonstrated that after 1972 this methodol-
ogy had a sensitivity of ~96% for veterans' deaths [28].
Statistical Analyses
Bivariate statistics were used to test the association of soci-
odemographic and clinical characteristics with all-cause
90-day mortality. Categorical variables were analyzed
using the Chi-square test and continuous variables were
analyzed using Student's t-test. Due to the number of sta-
tistical tests and the sample size of this database we set sta-
tistical significance at p ≤  0.001.
A propensity score technique was used to balance covari-
ates associated with medication use between groups [29-
31]. We created separate propensity scores for statins, ACE
inhibitors/ARBs, and to examine potential confounding,
non-statin lipid lowering medications. The propensity
score was derived from a logistic regression model. We
included variables in the propensity score if previous
research demonstrated a relationship between a variable
and COPD-related mortality, or if we hypothesized that it
may be related to prescription of the medications (e.g. ger-
iatric clinic use). Classes of medications included cardiac
medications (excluding ACE inhibitors, ARBs, statins, and
non-statin lipid lowering medications), diabetic medica-
tions, respiratory medications, inhaled corticosteroids,
and oral corticosteroids. The covariates included in the
propensity score models were age, gender, race, marital
status, socioeconomic status, classes of medications, and
the Charlson composite score. We then created an ordered
categorical variable based on a quintile stratification of
the propensity score to include in the regression models.
To analyze time-to-death for subjects by medication use
(statin or ACE inhibitor/ARB) we used Cox proportional
hazard models to estimate, and graph, the baseline survi-
vor functions after adjusting for the respective propensity
score.
Our primary analysis employed generalized linear mixed-
effect models with the patient's hospital as a random
effect and 90-day mortality as the dependent variable. We
created separate models with either ACE inhibitors or sta-
tin use as the independent variables of interest, and
adjusting for the appropriate propensity score. In addi-
tion, as secondary analyses we created similar models
with the dependent variable of 30-day mortality.
We used a similar methodology to examine the associa-
tion of non-statin lipid lowering drugs with 90-day mor-
tality after adjusting for potential confounders using the
appropriate propensity scores. We hypothesized that non-
statin lipid lowering medications would not be associated
with mortality since they have not been demonstrated to
have immunomodulatory effects.
In addition, to explore whether these associations with
mortality were only for those with pre-existing vascular
disease we repeated our analyses stratifying by the pres-
ence of specific comorbid conditions (e.g. myocardial inf-
arction, congestive heart failure, stroke, and diabetes).
All analyses were performed using STATA 9 (College Sta-
tion, Texas).
Results
Of the patients who had an inpatient stay in 2000 (n =
142,169), 11,212 subjects (7.9%) met our inclusion crite-
ria. The mean age was 74.0 years with a standard deviation
(SD) of 5.6 years, 42.0% of subjects were married, and
98.0% were male. In this cohort 12.8% were black, 82.3%
were white, 2.7% were Hispanic, and 2.2% were other/
unknown. In our cohort 6.5% of the subjects died within
30-days of presentation, and 12.4% died within 90-days
of presentation. Table 1 shows demographic and comor-
bid condition relationships with use of statins, ACE inhib-
itors, and/or ARBs. Factors significantly associated withRespiratory Research 2009, 10:45 http://respiratory-research.com/content/10/1/45
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receipt of the medications of interest included lower age,
not being married; history of myocardial infarction, con-
gestive heart failure, peripheral vascular disease, stroke,
diabetes with or without complications, and renal disease;
and not having a history of dementia. Table 2 shows the
variables examined and their relationship with 90-day
mortality. The only demographic variable associated with
90-day mortality in the bivariate analysis was increasing
age. Comorbid conditions associated with increased mor-
tality included congestive heart failure, renal disease,
malignancy, and metastatic solid tumors.
In our cohort 20.4% (n = 2286) were on statins, 30.4% (n
= 3404) were on ACE inhibitors, and 1.6% (n = 180) were
on ARBs. Due to the small number of subjects using ARBs,
for all analyses ACE inhibitor and ARB use was combined
into one variable. In the bivariate analyses, both statin
and ACE inhibitor use was significantly associated with
decreased 90-day mortality. No other medication classes
were significantly associated with mortality in our bivari-
ate analyses.
Figures 1 and 2 were created using Cox proportional haz-
ard models to estimate, and graph, the baseline survivor
functions for statin use (Figure 1) and ACE inhibitor use
(Figure 2) over the first 90-days after admission. After
adjusting for potential confounders, both statin and ACE
inhibitor use were significantly associated with improved
90-day survival (p < 0.0001).
In the multilevel models, after adjusting for the appropri-
ate propensity score and admitting hospital, prior use of a
statin (odds ratio (OR) 0.51, 95% confidence interval (CI)
0.40–0.64) and ACE inhibitor use (OR 0.55, 95% CI
0.45–0.66) were significantly associated with decreased
90-day mortality. For the outcome of 30-day mortality we
had similar findings with both statin (OR 0.51, 95% CI
0.41–0.64) and ACE inhibitor use (OR 0.58 95% CI,
0.48–0.70) associated with decreased 30-day mortality. In
addition, to examine whether there were significant inter-
actions between statins and ACE inhibitors use, we re-ran
our model with medication variables and the individual
potential confounders, rather than the propensity score.
Our results were similar with both prior use of a statin
(OR 0.47, 95% CI 0.37–0.60) and prior use of an ACE
inhibitor (OR 0.59, 95% CI 0.51–0.69) significantly asso-
ciated with decreased 90-day mortality, and there was no
significant interaction between the ACE inhibitor and sta-
tin use.
In addition, to examine whether use of both medication
classes may be associated with improved survival beyond
that observed in subjects using statins or ACE inhibitors
alone, we re-ran our model with 3 medication variables
Table 1: Characteristics of subjects (N = 11,212) with acute exacerbation of COPD by use of statin and/or ACE inhibitors versus non-
users of either medication*
Variables Users of statins or ACE inhibitors
(N = 4711)
Non-users
(N = 6501)
P-value
Age (mean, SD) 73.5 (5.4) 74.3 (5.8) <0.0001
Men 4616 (98) 6377 (98) 0.7
Race
White 3829 (81) 5397 (83)
Black 653 (45) 785 (54)
Hispanic 124 (3) 176 (3) 0.04
Married 2219 (47) 2492 (39) <0.0001
Charlson Comorbid Conditions
Myocardial infarction 956 (20) 568 (9) <0.0001
Congestive heart failure 2565 (54) 2001 (30) <0.0001
Peripheral vascular disease 881 (19) 880 (14) <0.0001
Stroke 867 (18) 819 (13) <0.0001
Peptic ulcer 368 (8) 493 (8) 0.7
Rheumatologic disease 125 (3) 158 (2) 0.5
Mild liver disease 40 (0.8) 82 (1) 0.04
Dementia 156 (3) 324 (5) <0.0001
Diabetes 1678 (36) 1324 (20) <0.0001
Diabetes with complications 488 (10) 258 (4) <0.0001
Moderate Liver disease 19 (0.4) 36 (0.6) 0.3
Hemiplegia 72 (2) 70 (1) 0.04
Renal disease 480 (10) 393 (6) <0.0001
Any malignancy 913 (19) 1373 (21) 0.02
Metastatic solid tumor 134 (3) 245 (4) 0.008
*Data are presented as number (%) or mean (standard deviation)Respiratory Research 2009, 10:45 http://respiratory-research.com/content/10/1/45
Page 5 of 9
(page number not for citation purposes)
(statin use only, ACE inhibitor use only, or use of both
statins and ACE inhibitors) and the individual potential
confounders, rather than the propensity scores. We found
that all 3 groups were associated with decreased mortality:
ACE inhibitors alone (OR 0.62, 95% CI 0.53–0.73), stat-
ins alone (OR 0.49, 95% CI 0.39–0.61), and those using
both (OR 0.40, 95% CI 0.32–0.52).
To further examine whether these associations were only
for pre-existing comorbid conditions for which statins
and ACE inhibitors have been shown to be protective
(coronary artery disease, strokes, and diabetes) or poten-
tially protective (congestive heart failure) we repeated our
primary multivariable analyses stratified by each of these
conditions. Table 3 shows these results. Except for ACE
inhibitors in subjects with a history of stroke, all other
odds ratios and confidence intervals were statistically sig-
nificant and similar to the analyses including the entire
population.
In the multilevel model that examined non-statin lipid
lowering medication use there was no significant associa-
tion with mortality (OR 0.98, 95% CI 0.62–1.54).
Discussion
We found that prior outpatient use of statins and ACE
inhibitor was associated with decreased 90-day mortality
for subjects ≥ 65 years of age hospitalized with acute
COPD exacerbations. Further studies, including rand-
omized control trials, are needed to examine the impact of
statins and ACE inhibitors, both pre-hospitalization and
acute, for subjects who are at risk for acute exacerbation of
COPD and COPD-related mortality.
Our study supports the recent findings that subjects with
COPD, or hospitalized with acute exacerbation of COPD
who were on statins and/or ACE inhibitors at admission
had significantly improved outcomes [16-19]. Unfortu-
nately those studies were limited by having small sample
Table 2: Characteristics of subjects (N = 11,212) with COPD exacerbation by vital status at 90-days after admission*
Variables Alive Within 90 days
(N = 9825)
Dead within 90-days
(N = 1387)
P-value
Age, years mean (SD) 73.8 (5.6) 75.0 (5.8) <0.0001
Men 9627 (98) 1366 (98) 0.2
Race/ethnicity
White 8059 (82) 1167 (84)
Black 1276 (13) 162 (12)
Hispanic 269 (3) 31 (2) 0.1
Other/unknown 221 (2) 27 (2)
Married 4788 (49) 687 (50) 0.3
Comorbid conditions
Myocardial infarction 1335 (14) 189 (14) 0.97
Congestive heart failure 4800 (49) 741 (53) 0.001
Peripheral vascular disease 2703 (28) 404 (29) 0.2
Stroke 1012 (10) 153 (11) 0.4
Peptic ulcer 1411 (14) 173 (12) 0.06
Rheumatologic disease 511 (5) 62 (5) 0.2
Diabetes 3020 (31) 386 (28) 0.03
Diabetes with complications 1322 (13) 153 (11) 0.01
Liver disease, mild 291 (3) 56 (4) 0.03
Liver disease, moderate 41(0.4) 14 (1) 0.003
Hemiplegia 375 (4) 57 (4) 0.6
Dementia 415 (4) 65 (5) 0.4
Renal disease 943 (10) 180 (13) <0.0001
Any malignancy 3068 (31) 500 (36) <0.0001
Metastatic solid tumor 410 (4) 123 (9) <0.0001
Medications
ACE Inhibitor/ARB 3249 (33) 335 (24) <0.0001
Statin 2113 (22) 173 (13) <0.0001
Cardiac, count (SD) 4.8 (4.0) 4.7 (4.0) 0.7
Respiratory, count (SD) 4.4 (3.7) 4.4 (3.7) 0.7
Diabetic, count (SD) 3.0 (2.2) 3.0 (2.2) 0.5
Inhaled corticosteroids 2667 (27) 394 (28) 0.3
Oral corticosteroids 2650 (27) 390 (28) 0.4
*Data are presented as number (%) or mean (standard deviation).Respiratory Research 2009, 10:45 http://respiratory-research.com/content/10/1/45
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sizes at a single site [18,19], only examining in-hospital
mortality [16], and not adjusting for other major comor-
bidities that may be associated with clinical outcomes
[17]. In addition, only one prior study reported the
impact of ACE inhibitor use on COPD-related mortality
[17].
Soyseth and colleagues [18] examined 854 patients who
were hospitalized with acute exacerbation of COPD from
a single Norwegian hospital, and followed them for a
median of 1.9 years. They found that statins (hazard ratio
(HR) 0.57, 95% CI 0.38–0.87) and statins along with
inhaled corticosteroids (HR 0.39, 95% CI 0.22–0.67)
were associated with decreased long-term mortality.
Frost and colleagues published a paper in Chest [16],
which described a cohort study and 2 small case-control
studies (397 patients with influenza and 207 patients
with COPD-related deaths) to examine the association of
statin therapy with mortality. They found that for those
subjects who received > 4 mg/day of statins for at least 90-
days prior to death had significantly lower odds of death
from influenza/pneumonia (OR 0.60, 95% CI 0.44–0.81)
and COPD (OR 0.17, 95% CI 0.07–0.42). Unfortunately
this study was limited by including only examining in-
hospital mortality and using discharge diagnosis as the
cause of death, problems with the exposure definition
[32], not adjusting for steroid use, and not using tech-
niques to minimize immortal time bias [33], which is
defined as a span of follow-up during which, because of
exposure definition, the outcome under study could not
occur [34].
Mancini and colleagues [17] conducted a nested case-con-
trol study of subjects with COPD from 2 different popula-
tions: one of which only included patients who had
recently undergone coronary revascularization and a sec-
ond with no history of myocardial infarction but newly
started on nonsteroidal anti-inflammatory drugs. Their
multivariable models adjusted for other cardiac medica-
tions, pulmonary medications, and previous hospitaliza-
tion for congestive heart failure and pneumonia.
Mancini's findings suggested that statin use was associated
with lower rates of hospitalization for COPD, myocardial
infarction (MI), and all-cause mortality for both low- and
high-risk cardiovascular groups. ACE inhibitors and ARBs
were associated with lower mortality in both groups but
had variable associations for MI and no significant associ-
ation with hospitalization for COPD. However, the
researchers failed to adjust for major comorbid conditions
that are associated with mortality and hospitalization
such as a prior stroke, diabetes, peripheral vascular dis-
ease, etc., in their multivariable models [24,35]. In addi-
tion, they did not provide the number of subjects exposed
to the medications of interests in the various case-control
groups. In contrast to Soyseth's [18] paper they found no
significant impact of steroid use upon the clinical out-
comes examined, but they examined both oral and
Proportion of surviving patients hospitalized with COPD exacerbation by use of statin versus non-use (p < 0.0001) Figure 1
Proportion of surviving patients hospitalized with COPD exacerbation by use of statin versus non-use (p < 
0.0001).
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inhaled corticosteroid use together in their models rather
than separately.
Although our study was a large database analysis and sub-
ject to the recognized limitations of such studies, we care-
fully assembled our cohort from complete patient
discharge data to avoid ascertainment bias. Our sample
was predominantly men due to our use of VA administra-
tive data, and it is possible that women may have differen-
tial responsiveness to these medications as compared to
men. Unfortunately due to the lack of pulmonary func-
tion data in these databases we had to rely upon ICD-9
codes and medication use to define COPD. However, a
recent publication by Joo et al. demonstrated that using a
similar methodology that > 90% of subjects classified as
having COPD were GOLD class 3–4 [21]. In addition,
prior studies have demonstrated that clinicians frequently
treat patients without this data [36], and we have no rea-
son to believe that there would be differences between
those exposed to the medications of interest versus the
non-exposed. Also as this was an administrative database
study we were unable to verify the diagnosis of COPD
exacerbation. However a similar definition has been pre-
viously used for another study of acute exacerbations of
COPD [37]. Also, we are unable to assess factors such as
inpatient management of the COPD exacerbation, inpa-
tient continuation of the statins/ACE inhibitors or the
dose effect due to the lack of availability of these data. Fur-
ther research is needed to examine these factors. Finally, as
in any non-experimental study, we are unable to state con-
clusively that the prior outpatient use of statins and/or
ACE inhibitors is the cause of decreased mortality, espe-
cially since we are unable to examine causes of death.
However, since subjects on these medications have
numerous medical conditions that are significantly asso-
ciated with increased short-term mortality, and our analy-
ses were adjusted for several factors that are associate with
patient frailty or "healthy user bias", we feel that we have
good evidence that these medications may have beneficial
Proportion of surviving patients hospitalized with COPD exacerbation by use of ACE inhibitor versus non-use (p < 0.001) Figure 2
Proportion of surviving patients hospitalized with COPD exacerbation by use of ACE inhibitor versus non-use 
(p < 0.001).
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Table 3: Results of multilevel models by history of specific 
comorbidities
History of comorbid condition
Yes No
Myocardial infarction
ACE inhibitor 0.60 (0.43–0.85) 0.63 (0.54–0.74)
Statin 0.39 (0.27–0.58) 0.53 (0.44–0.65)
Congestive heart failure
ACE inhibitor 0.61 (0.51–0.74) 0.59 (0.47–0.73)
Statin 0.63 (0.51–0.80) 0.37 (0.29–0.49)
Stroke
ACE inhibitor 0.75 (0.54–1.05) 0.61 (0.52–0.71)
Statin 0.41 (0.27–0.63) 0.54 (0.44–0.65)
Diabetes
ACE inhibitor 0.62 (0.47–0.80) 0.66 (0.56–0.78)
Statin 0.49 (0.36–0.67) 0.54 (0.44–0.66)
* Results reported as odds ratio (95% confidence interval)Respiratory Research 2009, 10:45 http://respiratory-research.com/content/10/1/45
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effects for subjects hospitalized with acute COPD exacer-
bations.
A strength of our study is that our cohort has the same
access to medical care, and low to no-cost prescriptions
due to the structure of the VA health care system [38]. In
addition, we adjusted for important sociodemographic
characteristics and comorbid conditions in our models.
Future observational studies need to adjust for these, and
other potential characteristics, that may impact the pre-
scription and use of these medications. Finally, our defini-
tion of medication exposure and follow-up minimized
potential immortal time bias.
Conclusion
In conclusion, our study finds that prior outpatient use of
statins and ACE inhibitors was associated with decreased
mortality for subjects hospitalized with acute COPD exac-
erbations. These results add an additional potential bene-
fit of statin and ACE inhibitor use to the already
compelling data for their use in subjects with vascular dis-
ease and diabetes. Randomized trials are needed to con-
firm the magnitude of the impact of statin and ACE
inhibitor use, either pre-hospitalization or acute, on sub-
jects hospitalized with acute exacerbation of COPD and to
elucidate the mechanism(s) by which they may work.
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